These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 23483464)

  • 1. [Eslicarbazepine acetate in clinical practice. Efficacy and safety results].
    Serrano-Castro PJ; Payán-Ortiz M; Cimadevilla JM; Quiroga-Subirana P; Fernández-Pérez J
    Rev Neurol; 2013 Mar; 56(6):309-14. PubMed ID: 23483464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neurological adverse events of new generation sodium blocker antiepileptic drugs. Meta-analysis of randomized, double-blinded studies with eslicarbazepine acetate, lacosamide and oxcarbazepine.
    Zaccara G; Giovannelli F; Maratea D; Fadda V; Verrotti A
    Seizure; 2013 Sep; 22(7):528-36. PubMed ID: 23623245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eslicarbazepine acetate in epilepsies with focal and secondary generalised seizures: systematic review of current evidence.
    Willems LM; Zöllner JP; Paule E; Schubert-Bast S; Rosenow F; Strzelczyk A
    Expert Rev Clin Pharmacol; 2018 Mar; 11(3):309-324. PubMed ID: 29285947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and tolerability of brivaracetam compared to lacosamide, eslicarbazepine acetate, and perampanel as adjunctive treatments in uncontrolled focal epilepsy: Results of an indirect comparison meta-analysis of RCTs.
    Brigo F; Bragazzi NL; Nardone R; Trinka E
    Seizure; 2016 Nov; 42():29-37. PubMed ID: 27710868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group phase III study.
    Elger C; Halász P; Maia J; Almeida L; Soares-da-Silva P;
    Epilepsia; 2009 Mar; 50(3):454-63. PubMed ID: 19243424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two-year follow-up with eslicarbazepine acetate: a consecutive, retrospective, observational study.
    Correia FD; Freitas J; Magalhães R; Lopes J; Ramalheira J; Lopes-Lima J; Chaves J
    Epilepsy Res; 2014 Oct; 108(8):1399-405. PubMed ID: 25060997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of eslicarbazepine acetate monotherapy for partial-onset seizures: Experience from a multicenter, observational study.
    Toledano R; Jovel CE; Jiménez-Huete A; Bayarri PG; Campos D; Gomariz EL; Giráldez BG; García-Morales I; Falip M; Agredano PM; Palao S; Prior MJAA; Pascual MRQ; Navacerrada FJ; González FJL; Ojeda J; Sáez AA; Bermejo PE; Gil-Nagel A
    Epilepsy Behav; 2017 Aug; 73():173-179. PubMed ID: 28641170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjunctive eslicarbazepine acetate: A pooled analysis of three phase III trials.
    Biton V; Rogin JB; Krauss G; Abou-Khalil B; Rocha JF; Moreira J; Gama H; Trinka E; Elger CE; Cheng H; Grinnell T; Blum D;
    Epilepsy Behav; 2017 Jul; 72():127-134. PubMed ID: 28575761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term efficacy and safety of eslicarbazepine acetate: results of a 1-year open-label extension study in partial-onset seizures in adults with epilepsy.
    Halász P; Cramer JA; Hodoba D; Członkowska A; Guekht A; Maia J; Elger C; Almeida L; Soares-da-Silva P;
    Epilepsia; 2010 Oct; 51(10):1963-9. PubMed ID: 20662896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EARLY-ESLI study: Long-term experience with eslicarbazepine acetate after first monotherapy failure.
    Villanueva V; Bermejo P; Montoya J; Toledo M; Gómez-Ibáñez A; Garcés M; Vilella L; López-González FJ; Rodriguez-Osorio X; Campos D; Martínez P; Giner P; Zurita J; Rodríguez-Uranga J; Ojeda J; Mauri JA; Camacho JL; Ruiz-Giménez J; Poza JJ; Massot-Tarrús A; Galiano ML; Bonet M
    Acta Neurol Scand; 2017 Sep; 136(3):254-264. PubMed ID: 27935017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of eslicarbazepine-acetate in elderly patients with focal epilepsy: Case series.
    Gómez-Ibáñez A; Serratosa JM; Guillamón E; Garcés M; Giráldez BG; Toledo M; Salas-Puig J; López-González FJ; Rodríguez-Uranga J; Castillo A; Mauri JA; Camacho JL; López-Gomáriz E; Giner P; Torres N; Palau J; Molins A; Villanueva V
    Seizure; 2017 May; 48():53-56. PubMed ID: 28419947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A common reference-based indirect comparison meta-analysis of eslicarbazepine versus lacosamide as add on treatments for focal epilepsy.
    Brigo F; Trinka E; Bragazzi NL; Nardone R; Milan A; Grillo E
    Epilepsy Res; 2016 Nov; 127():12-18. PubMed ID: 27543806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eslicarbazepine acetate add-on for drug-resistant partial epilepsy.
    Chang XC; Yuan H; Wang Y; Xu HQ; Zheng RY
    Cochrane Database Syst Rev; 2011 Dec; (12):CD008907. PubMed ID: 22161441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical experience with eslicarbazepine acetate in adults with sub-analysis of elderly.
    Nielsen MK; Petrenaite V; Andersen NB
    Seizure; 2017 Dec; 53():94-99. PubMed ID: 29172139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eslicarbazepine acetate as a replacement for levetiracetam in people with epilepsy developing behavioral adverse events.
    Jalihal V; Shankar R; Henley W; Parrett M; Tittensor P; McLean BN; Ahmed A; Sander JW
    Epilepsy Behav; 2018 Mar; 80():365-369. PubMed ID: 29415871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term safety and efficacy of eslicarbazepine acetate as adjunctive therapy in the treatment of partial-onset seizures in adults with epilepsy: results of a 1-year open-label extension study.
    Hufnagel A; Ben-Menachem E; Gabbai AA; Falcão A; Almeida L; Soares-da-Silva P
    Epilepsy Res; 2013 Feb; 103(2-3):262-9. PubMed ID: 22871333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eslicarbazepine acetate as adjunctive therapy in clinical practice: ESLADOBA study.
    Chaves J; Breia P; Pimentel J; Pelejão R; Carvalho M; Mateus P; Grebe H; Mestre A; Fernandes H; Sousa R; Gala A
    Acta Neurol Scand; 2017 Nov; 136(5):407-413. PubMed ID: 28181220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Social cognition and cognitive functions in patients with epilepsy treated with eslicarbazepine acetate].
    Abraira L; Sanabria A; Ortega G; Quintana M; Santamarina E; Salas-Puig J; Toledo M
    Rev Neurol; 2018 Jun; 66(11):361-367. PubMed ID: 29790568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term safety and efficacy of eslicarbazepine acetate in patients with focal seizures: results of the 1-year ESLIBASE retrospective study.
    Villanueva V; Serratosa JM; Guillamón E; Garcés M; Giráldez BG; Toledo M; Salas-Puig J; López González FJ; Flores J; Rodríguez-Uranga J; Castillo A; Mauri JA; Camacho JL; López-Gomáriz E; Giner P; Torres N; Palau J; Molins A
    Epilepsy Res; 2014 Sep; 108(7):1243-52. PubMed ID: 24908564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eslicarbazepine acetate: its effectiveness as adjunctive therapy in clinical trials and open studies.
    Shorvon SD; Trinka E; Steinhoff BJ; Holtkamp M; Villanueva V; Peltola J; Ben-Menachem E
    J Neurol; 2017 Mar; 264(3):421-431. PubMed ID: 28101651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.